Literature DB >> 23989776

Irreversible kinase inhibitors gain traction.

Katharine Sanderson.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23989776     DOI： 10.1038/nrd4103

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

1.  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Zachary Herrera; Megan Albertelli; Chaitan Khosla
Journal:  J Med Chem       Date:  2014-10-31       Impact factor: 7.446

Review 2.  The impact of structural biology in medicine illustrated with four case studies.

Authors:  Tiancen Hu; Elizabeth R Sprague; Michelle Fodor; Travis Stams; Kirk L Clark; Sandra W Cowan-Jacob
Journal:  J Mol Med (Berl)       Date:  2017-07-01       Impact factor: 4.599

Review 3.  Global discovery of protein kinases and other nucleotide-binding proteins by mass spectrometry.

Authors:  Yongsheng Xiao; Yinsheng Wang
Journal:  Mass Spectrom Rev       Date:  2014-11-05       Impact factor: 10.946

4.  Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue.

Authors:  Wentao Chen; Jiajia Dong; Lars Plate; David E Mortenson; Gabriel J Brighty; Suhua Li; Yu Liu; Andrea Galmozzi; Peter S Lee; Jonathan J Hulce; Benjamin F Cravatt; Enrique Saez; Evan T Powers; Ian A Wilson; K Barry Sharpless; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2016-06-02       Impact factor: 15.419

5.  Thiol Probes To Detect Electrophilic Natural Products Based on Their Mechanism of Action.

Authors:  Gabriel Castro-Falcón; Dongyup Hahn; Daniela Reimer; Chambers C Hughes
Journal:  ACS Chem Biol       Date:  2016-06-28       Impact factor: 5.100

Review 6.  Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Rev Hematol       Date:  2018-02-12       Impact factor: 2.929

Review 7.  Protein tyrosine phosphatases as potential therapeutic targets.

Authors:  Rong-Jun He; Zhi-Hong Yu; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

8.  Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.

Authors:  Pengfei Ma; Yujie Fu; Minjiang Chen; Ying Jing; Jie Wu; Ke Li; Ying Shen; Jian-Xin Gao; Mengzhao Wang; Xiaojing Zhao; Guanglei Zhuang
Journal:  Theranostics       Date:  2016-05-24       Impact factor: 11.556

Review 9.  FAK inhibitors as promising anticancer targets: present and future directions.

Authors:  Muhamad Mustafa; Amer Ali Abd El-Hafeez; Dalia A Abdelhafeez; Dalia Abdelhamid; Yaser A Mostafa; Pradipta Ghosh; Alaa M Hayallah; Gamal El-Din A Abuo-Rahma
Journal:  Future Med Chem       Date:  2021-08-03       Impact factor: 4.767

10.  Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.

Authors:  Vernon Seow; Junxian Lim; Adam J Cotterell; Mei-Kwan Yau; Weijun Xu; Rink-Jan Lohman; W Mei Kok; Martin J Stoermer; Matthew J Sweet; Robert C Reid; Jacky Y Suen; David P Fairlie
Journal:  Sci Rep       Date:  2016-04-20       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.